NewAmsterdam Pharma (NASDAQ:NAMS) Stock Rating Lowered by Wall Street Zen

NewAmsterdam Pharma (NASDAQ:NAMS) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

NAMS has been the topic of a number of other reports. Leerink Partners reiterated an “outperform” rating and set a $55.00 price objective on shares of NewAmsterdam Pharma in a research note on Tuesday, January 6th. Royal Bank Of Canada upped their target price on shares of NewAmsterdam Pharma from $44.00 to $47.00 and gave the company an “outperform” rating in a research note on Wednesday, January 21st. The Goldman Sachs Group lifted their price target on NewAmsterdam Pharma from $30.00 to $37.00 and gave the stock a “neutral” rating in a research note on Tuesday, December 2nd. HC Wainwright upgraded NewAmsterdam Pharma to a “strong-buy” rating in a research note on Thursday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of NewAmsterdam Pharma in a report on Thursday. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, NewAmsterdam Pharma currently has a consensus rating of “Moderate Buy” and an average target price of $47.00.

NewAmsterdam Pharma Stock Up 2.7%

Shares of NASDAQ NAMS opened at $35.58 on Friday. NewAmsterdam Pharma has a fifty-two week low of $14.06 and a fifty-two week high of $42.00. The business has a 50 day moving average price of $33.97 and a two-hundred day moving average price of $32.68. The firm has a market cap of $4.03 billion, a PE ratio of -20.57 and a beta of 0.06.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its earnings results on Wednesday, February 18th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.23). NewAmsterdam Pharma had a negative net margin of 906.22% and a negative return on equity of 26.67%. The business had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.92 million. On average, analysts anticipate that NewAmsterdam Pharma will post -1.75 earnings per share for the current year.

Insider Buying and Selling

In related news, CAO Louise Frederika Kooij sold 75,117 shares of the company’s stock in a transaction on Tuesday, December 23rd. The stock was sold at an average price of $36.21, for a total transaction of $2,719,986.57. Following the completion of the transaction, the chief accounting officer directly owned 15,000 shares in the company, valued at $543,150. This represents a 83.35% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Johannes Jacob Piete Kastelein sold 6,000 shares of the stock in a transaction on Monday, January 5th. The stock was sold at an average price of $33.25, for a total value of $199,500.00. Following the completion of the sale, the insider directly owned 73,481 shares in the company, valued at $2,443,243.25. This represents a 7.55% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 298,647 shares of company stock valued at $10,236,050. 20.84% of the stock is currently owned by insiders.

Hedge Funds Weigh In On NewAmsterdam Pharma

Hedge funds and other institutional investors have recently modified their holdings of the company. Frazier Life Sciences Management L.P. increased its holdings in shares of NewAmsterdam Pharma by 1.4% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 16,943,774 shares of the company’s stock worth $594,388,000 after acquiring an additional 241,818 shares during the period. Capital World Investors grew its position in NewAmsterdam Pharma by 1.6% in the 4th quarter. Capital World Investors now owns 9,984,000 shares of the company’s stock worth $350,239,000 after purchasing an additional 161,289 shares during the last quarter. Jennison Associates LLC grew its position in NewAmsterdam Pharma by 42.5% in the 3rd quarter. Jennison Associates LLC now owns 4,198,554 shares of the company’s stock worth $119,407,000 after purchasing an additional 1,252,451 shares during the last quarter. Wellington Management Group LLP increased its stake in shares of NewAmsterdam Pharma by 21.0% in the third quarter. Wellington Management Group LLP now owns 4,020,126 shares of the company’s stock valued at $114,332,000 after purchasing an additional 697,129 shares during the period. Finally, Adage Capital Partners GP L.L.C. raised its holdings in shares of NewAmsterdam Pharma by 54.5% during the second quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock valued at $54,566,000 after buying an additional 1,062,359 shares during the last quarter. Institutional investors and hedge funds own 89.89% of the company’s stock.

Trending Headlines about NewAmsterdam Pharma

Here are the key news stories impacting NewAmsterdam Pharma this week:

• Positive Sentiment: HC Wainwright published a bullish note/upgrade on NAMS, reinforcing a constructive view that likely supported buying interest. NewAmsterdam Pharma (NASDAQ:NAMS) Upgraded at HC Wainwright
• Positive Sentiment: HC Wainwright’s detailed model shows a path from near‑term losses to large, positive earnings in later years (FY2026 loss narrowing, then EPS of $2.36 in FY2027, $3.83 in FY2028, $7.02 in FY2029 and $7.87 in FY2030). That multi‑year upside projection is a clear bullish catalyst for growth‑oriented investors.
• Neutral Sentiment: HC Wainwright’s near‑term quarterly estimates still show losses (Q1/Q2/Q4 2026 EPS around -$0.34 to -$0.35), so the firm’s upgrade is more about long‑term potential than immediate profit improvement.
• Negative Sentiment: Wall Street Zen lowered NAMS to a Sell, creating analyst disagreement that can increase intraday volatility and limit momentum from bullish notes. NewAmsterdam Pharma (NASDAQ:NAMS) Lowered to Sell Rating by Wall Street Zen
• Negative Sentiment: Recent reported results showed a quarterly EPS miss and almost no revenue, underscoring execution and near‑term commercial risk that could undermine enthusiasm if fundamentals don’t improve.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.